



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 21 Feb 2022 (#7)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- **Financial Conflict of Interest:** The NIH is committed to preserving the public's trust that the research we supports is conducted without bias and with the highest scientific and ethical standards. The regulation on promoting objectivity in research establishes the standards to provide a reasonable expectation that the design, conduct, and reporting of NIH research will be free from bias resulting from investigators' financial conflicts of interest. NIH requires recipient [institutions](#) and investigators to comply with the requirements of [42 CFR 50, Subpart F, Promoting Objectivity in Research](#) (FCOI Regulation), as implemented in [Final Rule](#) for grants and cooperative agreements.

**Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office) not later than 31 March 2022.** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.

- FHMS contact: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)
- Stellenbosch Campus contact [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za).

**Link to the training:** [https://grants.nih.gov/grants/policy/coi/tutorial2018/story\\_html5.html](https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html)

Training on the Stellenbosch University policy on FCOI, which is also a requirement of **42 CFR 50**, will be offered soon and will be communicated through this newsletter and other communication channels.

- **[NOT-OD-21-110](#) Implementation of Changes to the Biographical Sketch and Other Support Format Page.** This notice describes implementation of the updated Other Support and Biosketch format pages and associated instructions, as outlined in [NOT-OD-21-073](#). NIH will require the use of the updated format pages. Failure to follow the appropriate formats on or after January 25, 2022 may cause NIH to withdraw applications from funding. Use of ScienCV Biosketch <https://www.ncbi.nlm.nih.gov/sciencv/> is strongly recommended. NIH is fully committed to implementing the SciENcv template for Other Support in early FY 2022. Examples are available from [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za).
- **[NOT-OD-22-055](#) FY 2022 Updated Guidance: Requirement for Instruction in the Responsible Conduct of Research.** By way of this Notice, the National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), and Health Resources & Services Administration (HRSA) reaffirm the principle that education in the responsible conduct of research is a fundamental element of research training and announce updates to their existing policy and guidance for such instruction. In particular, this Notice provides new recommendations on the format, frequency, and timing of instruction in the responsible conduct of research (RCR) and suggests additional topics for consideration.

- [The South African Fulbright Foreign Student Program](#) provides grants for South African university graduates to pursue post-graduate studies at a United States university in any subject (excludes MBA and studies that require contact with patients). Applications deadline: **May 1, 2022**. The following opportunities are available:
  - **Non-degree:** South African PhD students enrolled with a South African University may apply to conduct one year's research at a U.S. University as a Visiting Student Researcher (VSR). Current National Research Foundation (NRF) funded PhD students are encouraged to apply.
  - **Masters/PhD:** Post-graduate students may apply for scholarships towards Master's or Doctorate degrees. Scholarships are awarded for two years towards one degree – Master's or Doctorate.
- In early 2022, NIH's National Library of Medicine (NLM) introduced a new beta version of [ClinicalTrials.gov](#), a website and online database providing clinical research studies and results to the public, researchers, and healthcare professionals. For a general overview and FAQ, go to [About Clinical Trials.gov](#).
- The [Centers of Excellence for Influenza Research and Response \(CEIRR\)](#) is an NIAID-supported international research network to study influenza and provide research infrastructure to combat influenza outbreaks. CEIRR invites you to consider the new [Pilot Research Program](#), a funding and collaboration opportunity for non-CEIRR investigators.
- [NOT-CA-22-052](#) Notice of Intent to Publish a Funding Opportunity Announcement for Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) (U54 Clinical Trials Optional). The National Cancer Institute (NCI) intends to issue a FO as an RFA (i.e., Request for Applications) for the "GlobalISE Cancer Control" Consortium (U54 Clinical Trial Optional). This RFA aims to support global implementation science in low- and middle-income countries (LMICs). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The centers funded through this consortium will work together to share research methods and measures, train U.S. and LMIC investigators in implementation science, and engage with implementers across community and health systems. **Estimated Application Due Date:** 25 September 2022. **Expected Number of Awards:** 4. **Estimated Award Ceiling:** \$500,000 Direct Costs per year for a total of five years.

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices of Special Interest

- [NOT-DA-22-003](#) Notice of Special Interest (NOSI): Public Health Research on Cannabis. The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health. This notice applies to due dates on or after 5 June 2022 and subsequent receipt dates through 5 May 2025.

- [NOT-DA-22-056](#) Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders.** There is an urgent public health need for the expansion of available therapeutic options for individuals with Opioid and Polysubstance Use Disorders as the efficacy of many treatments decrease over the long-term. The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments. In response to this public health need, the HEAL Initiative will consider funding scientifically meritorious applications that focus on evaluating the safety and/or the efficacy of digital therapeutics to opioid use disorders alone or in combination with other Substance Use Disorders (SUD) that are submitted in response to [PAR-21-183](#). This notice applies to due dates on or after 6 April 2022 and subsequent receipt dates through 7 December 2023.
- [NOT-EY-22-004](#) Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities.** The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting research that aims to promote health equity in the prevention, treatment, and management of eye and vision conditions. Applications that target reduction of health disparities experienced by people who are visually impaired or blind are encouraged, as well as applications that investigate the impact of bias, structural racism, and discrimination in causing or sustaining eye or vision health inequities. This notice applies to due dates on or after 25 May 2022 and subsequent receipt dates through 25 January 2025.
- [NOT-HD-21-048](#) Notice of Special Interest (NOSI): Research on Drowning Prevention.** The US and global burden of drowning, and the need for research prioritization, was highlighted in two recent American Academy of Pediatrics reports (2019 and 2021) and several World Health Organization documents. Moreover, on April 28, 2021, governments worldwide adopted the first ever United Nations General Assembly Resolution focused on global drowning prevention. Drowning is a foremost cause of child death. In the United States (US), drowning is the leading cause of injury death in children ages 1-4 years and a leading cause of unintentional injury death in children ages 5-19 years. Globally, nearly 300,000 annual drowning deaths occur; 90% of which are in low- and middle-income countries (LMIC) and young children have the highest death rates. Morbidity from drowning is also high with more than 50% of US drowning victims who receive emergency department care requiring hospitalization or higher-level care. When drowning victims survive, they can suffer severe organ damage, including long-term neurologic impairment and disability. This notice applies to due dates on or after 5 June 2022 and subsequent receipt dates through 8 May 2024.
- [NOT-NS-22-001](#) Notice of Special Interest (NOSI): Postmortem Pathology, Cellular, and Molecular Analyses to Determine the Significance of White Matter Lesions and other Imaging Findings of Presumed Vascular Origin During Life.** This NINDS Notice of Special Interest (NOSI) announces the availability of administrative supplements to support examination of human in-vivo magnetic resonance imaging (MRI) findings of presumed vascular origin (vascular contributions to cognitive impairment and dementia, VCID) as they relate to post-mortem pathology of AD/ADRD. Of interest are brain lesions resulting from dysfunctional vasculature or vascular processes, such as white matter hyperintensities, infarcts (including cortical microinfarcts), and microbleeds, along with cellular, molecular, and in-depth post-mortem imaging and pathological data analysis. [PA-20-272](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) All supplement applications must be received by 1 April 2022. Requests may be for two years of support only. Application budgets must reflect the actual needs of the proposed project. Supplement budget requests are limited to 100% of the direct costs of the current year of the parent award (exclusive of Facilities and Administrative costs on sub-contracts) and may not exceed \$500,000 in total costs per year. Applications that want to propose higher budgets must receive permission from the project officer and IC Contact prior to submission. Awards made under this NOSI are limited to one per parent award.

## Funding Opportunity Announcements (FOA)

### 1. Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-085](#)

**Type:** R01

**Application Due Date:** 5 June 2022 through to 5 February 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader [NCI-sponsored research on microbial based cancer therapy](#).

**Companion Funding:** [PAR-22-086](#), [R21](#) Exploratory/Developmental Grants

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

### 2. Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-086](#)

**Type:** R21

**Application Due Date:** 16 June 2022 through to 16 February 2025. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader [NCI-sponsored research on microbial based cancer therapy](#).

**Companion Funding:** [PAR-22-085](#), [R01](#) Research Project

**Budget:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

### 3. Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-117](#)

**Type:** R01

**Application Due Date:** 31 March 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement.** The Vision Research Collaborative (VRC) is a joint initiative between the National Eye Institute (NEI) and the Congressionally Directed Medical Research Programs (CDMRP) Vision Research Program (VRP) of the Department of Defense (DOD). The goal of this partnership is to provide additional funding opportunities for VRP proposals, enhance current NEI Program portfolios, expand the scope of research supported by the NEI, and provide support for high quality projects addressing critical gaps in civilian and military vision research. Only PI's who have received an invitation from the NEI to submit a reformatted application to the NIH will be considered.

**Budget:** Application budgets must not exceed the limits stated in the VRP Investigator-Initiated Research Award program announcement (<https://cdmrp.army.mil/funding/pa/FY21-VRP-IIRA.pdf>) or Award announcement (<https://cdmrp.army.mil/funding/pa/FY21-VRP-TRA.pdf>).

### 4. In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DE-23-004](#)

**Type:** R01

**Application Due Date:** 14 June 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This FOA is intended to support research to accelerate the development of treatments for congenital dental and craniofacial diseases and conditions. The FOA invites applications for projects that will use precision medicine approaches in animal models to develop *in utero* treatments for congenital dental and craniofacial diseases and conditions. It is anticipated that successful treatments can arrest, ameliorate, or cure the diseases or conditions of interest. The long-term goal is to lay the groundwork for delivery of *in utero* therapies and cures in humans affected by congenital dental and craniofacial diseases and conditions as well as other diseases and conditions that share similar disease etiologies.

**Companion Funding:** [RFA-DE-23-005](#), [R21](#) Exploratory/Developmental Grants

**Budget:** NIDCR intends to commit up to \$3,000,000 in FY2023 to support six to eight new R01 and R21 awards solicited through [RFA-DE-23-004](#) and [RFA-DE-23-005](#). Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

**Division for Research Development (DRD)  
Stellenbosch Campus**  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105